The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors dealings: Hikma chief dips back in after gout victory

Mon, 27th Jun 2016 14:24

(ShareCast News) - Hikma Pharmaceuticals chief executive Said Darwazah has further boosted his stake in the company with a huge £3.3m purchase of shares. Darwazah, whose father set up Hikma in 1978, showed his confidence in the company with a purchase of 150,000 shares at a price of 2,200p, almost a fortnight after he spent £1.52m on 70,000 shares.He now owns 13.3m shares, of 5.56% of the total.Drwazah's deals come a few weeks after a US court ruled in favour of Hikma and its wholly-owned US subsidiary West-Ward Pharmaceutical by dismissing claims made by Takeda Pharmaceuticals for alleged infringement of patents covering methods of use of Takeda's colchicine product, Colcrys, to treat gout.Hikma has been marketing its own colchicine product under the brand name Mitigare since January 2015 and selling an authorised generic.Gout, known as the 'disease of kings' as it afflicted many monarchs, including Henry VIII, is making a painful resurgence in the UK due to growing levels obesity and heavy drinking. Top Director BuysHikma Pharmaceuticals (HIK)Director name: Al-Husry,AliAmount purchased: 150,000 @ 2,200.00pValue: £3,300,000.00Hikma Pharmaceuticals (HIK)Director name: Darwazah,MazenAmount purchased: 150,000 @ 2,200.00pValue: £3,300,000.00Hikma Pharmaceuticals (HIK)Director name: Darwazah,SaidAmount purchased: 150,000 @ 2,200.00pValue: £3,300,000.00Royal Mail (RMG)Director name: Long,Peter JamesAmount purchased: 50,000 @ 471.40pValue: £235,700.01Watkin Jones (WJG)Director name: Turner,GrenvilleAmount purchased: 90,900 @ 106.40pValue: £96,717.60Auto Trader Group (AUTO)Director name: Keens,David WAmount purchased: 25,000 @ 358.49pValue: £89,622.50Savills (SVS)Director name: Ferguson,NicholasAmount purchased: 15,000 @ 587.39pValue: £88,108.80Electrocomponents (ECM)Director name: Ruth,LindsleyAmount purchased: 20,000 @ 266.00pValue: £53,200.00Is Solutions (ISL)Director name: Simmonds ,Peter Amount purchased: 40,000 @ 118.60pValue: £47,440.00Wpp (WPP)Director name: Susman,Simon Sally Amount purchased: 2,500 @ $21.29Value: $42,055.62Wpp (WPP)Director name: Seligman,NicoleAmount purchased: 2,500 @ $20.80Value: $41,083.23Taylor Wimpey (TW.)Director name: Barker ,Kate Amount purchased: 20,000 @ 134.77pValue: £26,953.44Informa (INF)Director name: Flaschen,DavidAmount purchased: 3,000 @ $9.05Value: $21,450.60Prudential (PRU)Director name: Turner,Lord J AdairAmount purchased: 1,500 @ 1,178.00pValue: £17,670.00Hogg Robinson Group (HRG)Director name: Krumins,JohnAmount purchased: 20,000 @ 64.81pValue: £12,962.00Primary Health Properties (PHP)Director name: Holland ,Phil Amount purchased: 10,000 @ 104.12pValue: £10,412.50Marshalls (MSLH)Director name: Allner,AndrewAmount purchased: 3,943 @ 253.58pValue: £9,998.66Marshalls (MSLH)Director name: Allner,AndrewAmount purchased: 3,927 @ 254.45pValue: £9,992.25Challenger Acquisitions Limited (CHAL)Director name: Gustafson,MarkAmount purchased: 30,000 @ 22.90pValue: £6,870.00Vertu Motors (VTU)Director name: Forrester,RobertAmount purchased: 11,215 @ 44.55pValue: £4,996.28Challenger Acquisitions Limited (CHAL)Director name: Gustafson,MarkAmount purchased: 20,000 @ 24.85pValue: £4,970.00Challenger Acquisitions Limited (CHAL)Director name: Gustafson,MarkAmount purchased: 20,000 @ 24.70pValue: £4,940.00Challenger Acquisitions Limited (CHAL)Director name: Gustafson,MarkAmount purchased: 20,000 @ 24.45pValue: £4,890.00Challenger Acquisitions Limited (CHAL)Director name: Gustafson,MarkAmount purchased: 20,000 @ 23.95pValue: £4,790.00Oxford Biomedica (OXB)Director name: Tallarigo ,Lorenzo Amount purchased: 62,847 @ 4.20pValue: £2,639.57
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.